Servier Announces Topline Results from Pivotal Sevasemten Study in Becker
Servier announced yesterday that the pivotal Phase 3 GRAND CANYON study evaluating sevasemten in individuals living with Becker muscular dystrophy did not meet its primary endpoint. Sevasemten is an orally administered small molecule inhibitor designed…Learn More
